Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 9/20 | 0.41 |
| ▸ | MMP13 | P45452 | 3/20 | 0.41 |
| ▸ | MMP2 | P08253 | 9/20 | 0.40 |
| ▸ | MMP3 | P08254 | 6/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | BMP1 | P13497 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | FCER2 | P06734 | 1/20 | 0.37 |
| ▸ | USP19 | O94966 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3320496 | 1.00 | MMP1 (0.41) | MMP1MMP13MMP2MMP3CTSS | |
| SCHEMBL3319461 | 0.83 | ATM (0.39) | MMP1MMP13MMP2MMP3BMP1 | |
| SCHEMBL3323173 | 0.82 | LTA4H (0.37) | MMP1MMP13MMP2MMP3CTSS | |
| SCHEMBL5494014 | 0.81 | MMP1 (0.44) | MMP1MMP13MMP2MMP3CTSS | |
| SCHEMBL5494009 | 0.81 | MMP1 (0.44) | MMP1MMP13MMP2MMP3CTSS | |
| SCHEMBL3324815 | 0.80 | CTSD (0.42) | MMP1MMP2MMP3CTSSFCER2 | |
| SCHEMBL3324823 | 0.80 | CTSD (0.42) | MMP1MMP2MMP3CTSSFCER2 | |
| SCHEMBL3320624 | 0.80 | ALDH1A1 (0.39) | SMN1; SMN2 | |
| SCHEMBL13333365 | 0.79 | LTA4H (0.34) | MMP1MMP13MMP2MMP3CTSS | |
| SCHEMBL5496205 | 0.79 | MMP1 (0.45) | MMP1MMP13MMP2MMP3CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100125075-A1 | Antibacterial Agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2010-05-20 | — | — | US | disclosed |
| US-6846825-B1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2005-01-25 | — | — | US | disclosed |
| EP-1202968-A2 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001010834-A9 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARM (GB) | 2001-08-09 | — | — | WO | disclosed |
| WO-2001010834-A2 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125075-A1 | Antibacterial Agents | NQO2, DAO, Q6ZSR9 | MMP1 3122/4885MMP13 3849/4885MMP2 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.